Inozyme Pharma, Inc.

NasdaqGS:INZY Stock Report

Market Cap: US$89.9m

Inozyme Pharma Management

Management criteria checks 2/4

Inozyme Pharma's CEO is Doug Treco, appointed in Apr 2023, has a tenure of 1.83 years. total yearly compensation is $5.30M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth $31.32K. The average tenure of the management team and the board of directors is 2.9 years and 6.8 years respectively.

Key information

Doug Treco

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage7.1%
CEO tenure1.8yrs
CEO ownership0.03%
Management average tenure2.9yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Nov 17
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Aug 03
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Jul 30

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Apr 11
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Mar 08

Inozyme Pharma GAAP EPS of -$0.38

Aug 15

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12
Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06
We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22
Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08
Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22
We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06
We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

CEO Compensation Analysis

How has Doug Treco's remuneration changed compared to Inozyme Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$89m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$375k

-US$71m

Sep 30 2023n/an/a

-US$68m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$106kn/a

-US$67m

Sep 30 2022n/an/a

-US$67m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$62m

Dec 31 2021US$188kn/a

-US$57m

Sep 30 2021n/an/a

-US$49m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$339kn/a

-US$56m

Compensation vs Market: Doug's total compensation ($USD5.30M) is above average for companies of similar size in the US market ($USD638.32K).

Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.

CEO

Doug Treco (66 yo)

1.8yrs

Tenure

US$5,299,476

Compensation

Dr. Douglas A. Treco, also known as Doug, Ph D., is an Advisor at LSV Capital Management LLC. Earlier he was a Scientific Advisor at the firm.He was Chief Executive Officer of Alchemab Therapeutics from A...

Leadership Team

NamePositionTenureCompensationOwnership
Douglas Treco
CEO & Chairman1.8yrsUS$5.30m0.035%
$ 31.3k
Axel Bolte
Co-Founderno dataUS$1.80m0.42%
$ 373.4k
Sanjay Subramanian
Senior VP2.9yrsUS$1.03m0.047%
$ 42.6k
Matthew Winton
Senior VP & COO1.8yrsUS$1.55m0.0076%
$ 6.9k
Demetrios Braddock
Co-Founderno datano datano data
Soojin Kim
Senior VP & Chief Technical Operations Officer2.9yrsno datano data
Stefan Riley
Director of Investor Relationsno datano datano data
Gayle Gironda
Senior VP & Chief People Officer3.6yrsno datano data
Yves Sabbagh
Chairman of Scientific Advisory Board & Senior VPno datano datano data
Stephen J. Palma
Consultant2.9yrsno datano data
Kurt Gunter
Senior VP & Chief Medical Officer2.7yrsno datano data

2.9yrs

Average Tenure

58.5yo

Average Age

Experienced Management: INZY's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Douglas Treco
CEO & Chairman4.8yrsUS$5.30m0.035%
$ 31.3k
Axel Bolte
Co-Founder9.4yrsUS$1.80m0.42%
$ 373.4k
Demetrios Braddock
Co-Founderno datano datano data
Yves Sabbagh
Chairman of Scientific Advisory Board & Senior VPno datano datano data
Martin Edwards
Independent Director7.4yrsUS$129.65k0%
$ 0
Reinaldo Diaz
Lead independent director8.1yrsUS$130.27k0%
$ 0
Joseph Schlessinger
Member of Scientific Advisory Boardno dataUS$135.00kno data
Edward Mathers
Independent Director8.1yrsUS$116.15k0%
$ 0
Robert Hopfner
Independent Director6.3yrsUS$112.15k0%
$ 0
Sarah Bhagat
Independent Director5.9yrsUS$114.65k0%
$ 0
Lynne Sullivan
Independent Director4.8yrsUS$122.15k0%
$ 0
Michael Levine
Chairperson of Clinical Advisory Boardno datano datano data

6.8yrs

Average Tenure

64yo

Average Age

Experienced Board: INZY's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 05:41
End of Day Share Price 2025/02/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inozyme Pharma, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Edward WhiteH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC